1. Patients and Families
  2. Clinical Trial Database
  3. Canadian clinical trial registry

Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

1 results found

Title
Status

 

ACNS1422 - A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Open

More information

ACNS1422 - A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Go to Health Care Provider version

DiagnosisMedulloblastomaStudy StatusOpen
PhaseII
Age3 Years to 21 YearsRandomisationNO
Line of treatmentFirst line treatment
Routes of Treatment AdministrationChemotherapy: Cisplatin (Given IV), Cyclophosphamide (Given IV), Lomustine (Given PO), Vincristine Sulfate (Given IV or via minibag) Radiation: Radiation Therapy
Last Posted Update2023-11-09
ClinicalTrials.gov #NCT02724579
International Sponsor
Children's Oncology Group
Principal Investigators for Canadian Sites
Alberta Children's Hospital - Dr. Victor Lewis
BC Children's Hospital - Dr. David Dix
CancerCare Manitoba - Dr. Ashley Chopek
Janeway Child Health Centre - Dr. Lisa Goodyear
IWK Health Centre - Dr. Craig Erker
McMaster Children's Hospital at Hamilton Health Sciences - Dr. Uma Athale
Western Children's Hospital - Dr. Shayna Zelcer
Children's Hospital of Eastern Ontario - Dr. Donna Johnston
Hospital for Sick Children - Dr. Vijay Ramaswamy
Montreal Children's Hospital - Dr. Genevieve Legault
Saskatoon Cancer Centre - Dr. Kathleen Felton
Centres
Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
 
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson

 

 

Medical contact
Dr. Paul Moorehead
 
Social worker/patient navigator contact
Stephanie Eason
 
Clinical research contact
Bev Mitchell
 
Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez 
Dr. Ketan Kulkarni 
 
Social worker/patient navigator contact
Rhonda Brophy
 
Clinical research contact
Tina Bocking
 
Medical contact
Dr. Carol Portwine
 
Social worker/patient navigator contact
Jane Cassano 
 
Clinical research contact
Sabrina Millson
 
 
Medical contact
Dr. Alexandra Zorzi
Dr. Shayna Zelcer
 
Social worker/patient navigator contact
Cindy Milne Wren
Jessica Mackenzie Harris
 
Clinical research contact
Mariam Mikhail
Medical contact
Dr. Donna Johnston
Dr. Lesleigh Abbott
Dr. Doaa Abdel Fattah
 
Social worker/patient navigator contact
Sherley Telisma
 
Clinical research contact
Carol Duchenne
 
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact
Dr. Chris Mpofu

 

 

Social worker/patient navigator contact
Jillian Galambos
La Rae Beebe

 

Clinical research contact
Susan Kaban

 

 

 

Study Description

This phase 2 trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT-driven medulloblastoma.

(via: https://childrensoncologygroup.org/acns1422)

Inclusion Criteria
  • Patients are between 3 years to 21 years old
  • Patient is newly diagnosed with average-risk medulloblastoma  in the WNT subgroup by institutional diagnosis
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.